Speaker Profile

Ph.D., CEO, Inflammatix

Dr. Sweeney cofounded Inflammatix following his clinical training as a surgeon at Stanford, where he was frequently frustrated with the lack of tools to determine which of his post-operative patients had infections and required antibiotics or evaluation for sepsis. He subsequently pursued post-doctoral research in biomedical informatics and, along with Inflammatix’s cofounder, Dr. Purvesh Khatri, developed the proprietary technology that powers the company’s tests, including its first test, HostDx Sepsis. Beyond his work at Inflammatix, Dr. Sweeney continues to actively give back to the community as a mentor to new startups in Stanford’s StartXMed program, as an editorial board member of Critical Care Medicine, and as a frequent ad-hoc peer reviewer for manuscripts in sepsis, bioinformatics, and machine learning.

Clinical Dx Showcase:

Inflammatix is a novel molecular diagnostics company focused on bringing advanced host-response diagnostics to the point of care in a rapid, small device. Its flagship test, HostDx Sepsis, is focused on diagnosing acute infection, but the company also has a deep diagnostics pipeline in acute infections and inflammatory disease based on the same computational techniques.

HostDx Diagnostics: Precision Medicine At The Point Of Care
Inflammatix’s HostDx(TM) tests combine advanced machine learning and computational biology to ‘read’ the immune response to create actionable insights that fit into rapid workflows. The company's novel device can measure dozens of novel markers in <30 minutes.

 Session Abstract – PMWC 2020 Silicon Valley

The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.